Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06699394
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Fuxing Hospital affiliated to Capital Medical University, Beijing, China
Ultrasound-based Artificial Intelligence for Classification of Carpal Tunnel Syndrome
- Conditions
- Carpal Tunnel Syndrome (CTS)UltrasoundArtificial Intelligence (AI)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06697392
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing. PR, China
Risk Stratification and MRD-driven Maintenance for MM After ASCT
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06697483
- Locations
- 🇨🇳
Fuxing Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Research on the Application of Patient Navigation-based Management Model of Patients After LEEP
- Conditions
- Cervical Intraepithelial Neoplasias
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT06695871
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
- Conditions
- Triple Negative Breast Cancer
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 380
- Registration Number
- NCT06692725
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer
- Conditions
- Neoadjuvant Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06682884
Haplo-HSCT for Myelofibrosis
- Conditions
- Myelofibrosis
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06674382
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Clinical Performance of Urine HPV Testing in Males
- Conditions
- HPVSelf-samplingMale
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06671210
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
- Conditions
- Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06671717
- Locations
- 🇨🇳
Peking University, Institute of Hematolgoy, Beijing,, Beijing, China
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Conditions
- Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia
- Interventions
- Biological: CAR-T(RD140 injection)
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06655519